论文部分内容阅读
据Neurex公司的一项皿期临床研究的中期结果报道，神经元特异性钙通道阻滞剂个C0ndide治疗神经病性疼痛有效。在这一研究中，患有神经病性疼痛的病人接受本品或安慰剂。对100多例病人的最新分析表明，本品组疼痛评分几乎降低了40％，而安慰剂组却没有变化。组间差异具有显著的
Interim results from a phase III clinical trial by Neurex reported that neuron-specific calcium channel blockers Cndide are effective in treating neuropathic pain. In this study, patients with neuropathic pain received this product or placebo. The latest analysis of more than 100 patients showed that the pain score was reduced by almost 40% in this product group compared with no change in the placebo group. Differences between groups were significant